Tracheal involvement in ulcerative colitis: clinical presentation and potential interest of 2-deoxy-2[18F]fluoro-d-glucose positron emission tomography (18F-FDG PET) for the management

2012 ◽  
Vol 26 (10) ◽  
pp. 830-834 ◽  
Author(s):  
Youenn Jouan ◽  
Yann Venel ◽  
Bertrand Lioger ◽  
Christophe Monegier du Sorbier ◽  
Luc Gaucher ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Clinical Presentation ◽  
Emission Tomography ◽  
Potential Interest ◽  
Positron Emission ◽  
18F Fdg

POSITRON EMISSION TOMOGRAPHY WITH 18F -FDG IN THE DIAGNOSIS OF PROSTHETIC HEART VALVE ENDOCARDITIS

2021 ◽  
Vol 5 (1) ◽  
pp. 1151-1160
Author(s):  
A.S. Lukashevich ◽  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Prosthetic Heart Valve ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Purpose. The purpose of the article is to evaluate the diagnostic significance of positron emission tomography / computed tomography with 18F -fluorodeoxyglucose (18F -FDG PET/CT) for the diagnosis of prosthetic endocarditis. Methods of research. The study included 82 patients with suspected prosthetic endocarditis in accordance with the criteria proposed by Duke University [1-5]. The patients received hospital treatment at the State Institution RSPC "Cardiology" from January 2016 to March 2021. The study was of a prospective, non-randomized, single-center cohort design. The duration of the monitor period was 12 months from the moment of patients’ inclusion in the study. Whole-body positron emission tomography / computed tomography (PET/CT) examinations were performed in 82 patients. 27 patients were selected for surgical treatment. Conservative treatment group included 16 patients. 27 patients were selected into the observation group, they were suspected to have prosthetic heart valve infection in the primary referral and underwent PET/CT scanning, according to which the diagnosis of prosthetic endocarditis was excluded. The event under the study did not develop in this group during the year of observation. Results and conclusion. The history of infective endocarditis was not statistically significant and did not increase the risk of developing prosthetic endocarditis in the sample presented. The Duke criteria are less reliable in establishing the diagnosis of prosthetic endocarditis. The median number of days from the date of the first prosthesis implantation to the onset of prosthetic endocarditis was about 4 years. This study revealed that the development of the infectious process in the area of the prosthesis was noted in a more distant postoperative period compared to literature data. Histological confirmation of infection was noted in 100% (27 patients) of cases in reoperated patients. The presence of a more formidable complication such as valve ring abscess located mainly in the projection of the aortic valve ring was quite common in both groups. Presepsin and Interleukin-6 have a statistically significant (U = 394,50 p = 0,01 and U = 94,50 p = 0.004) value in the prognosis of prosthetic endocarditis. Considering the data obtained from ROC analysis, it can be said that the cut-off point at which it is possible to diagnose prosthetic endocarditis based on PETCT is 2.85. The presented methods for the interpretation of whole-body FDG-PET/CT images of patients with suspected infectious complications after cardiac surgery, as well as with the presence of prosthetic endocarditis, show high sensitivity and specificity.

scholarly journals Clinical Impact of 18F-FDG PET/CT in the Diagnostic Workup of Pancreatic Ductal Adenocarcinoma: A Systematic Review

Diagnostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1042
Author(s):  
Annachiara Arnone ◽  
Riccardo Laudicella ◽  
Federico Caobelli ◽  
Priscilla Guglielmo ◽  
Marianna Spallino ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Ductal Adenocarcinoma ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

In this review, the performance of fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in the diagnostic workup of pancreatic ductal adenocarcinoma (PDAC) is evaluated. A comprehensive literature search up to September 2020 was performed, selecting studies with the presence of: sample size ≥10 patients and index test (i.e., “FDG” or “18F-FDG” AND “pancreatic adenocarcinoma” or “pancreas cancer” AND “PET” or “positron emission tomography”). The methodological quality was evaluated using the revised quality assessment of diagnostic accuracy studies (QUADAS-2) tool and presented according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Basic data (authors, year of publication, country and study design), patients’ characteristics (number of enrolled subjects and age), disease phase, type of treatment and grading were retrieved. Forty-six articles met the adopted research criteria. The articles were divided according to the considered clinical context. Namely, besides conventional anatomical imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), molecular imaging with FDG PET/CT is an important tool in PDAC, for all disease stages. Further prospective studies will be necessary to confirm the cost-effectiveness of such imaging techniques by testing its real potential improvement in the clinical management of PDAC.

Determinants of Response to Neoadjuvant Chemotherapy for Esophageal Cancer Using 18F-fluorodeoxiglucose Positron Emission Tomography (18F-FDG-PET)

2013 ◽  
Vol 21 (2) ◽  
pp. 575-582 ◽  
Author(s):  
Hiroshi Miyata ◽  
Makoto Yamasaki ◽  
Tsuyoshi Takahashi ◽  
Kohei Murakami ◽  
Koji Tanaka ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Esophageal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Positron Emission ◽  
18F Fdg ◽  
Response To Neoadjuvant Chemotherapy

The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer

1999 ◽  
Vol 9 (2) ◽  
pp. 117-122 ◽  
Author(s):  
SCHRODER ◽  
ZIMNY ◽  
RUDLOWSKI ◽  
BULL ◽  
RATH
Keyword(s):  
Ovarian Cancer ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Positron Emission ◽  
18F Fdg

Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: Comparison with 18F-FDG-PET

2013 ◽  
Vol 40 (5) ◽  
pp. 1121-1128 ◽  
Author(s):  
Nina F. Schwenzer ◽  
Holger Schmidt ◽  
Sergios Gatidis ◽  
Cornelia Brendle ◽  
Mark Müller ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Diffusion Coefficient ◽  
Apparent Diffusion Coefficient ◽  
Peritoneal Carcinomatosis ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Positron Emission ◽  
Apparent Diffusion ◽  
18F Fdg

scholarly journals Virtual Navigator Real-Time Ultrasound Fusion Imaging with Positron Emission Tomography/Computed Tomography for Preoperative Breast Cancer

Medicina ◽  
2021 ◽  
Vol 57 (12) ◽  
pp. 1289
Author(s):  
Mio Mori ◽  
Kazunori Kubota ◽  
Tomoyuki Fujioka ◽  
Leona Katsuta ◽  
Yuka Yashima ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Fusion Imaging ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

We used virtual navigator real-time ultrasound (US) fusion imaging with 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to identify a lesion that could not be detected on the US alone in a preoperative breast cancer patient. Of the patient’s two lesions of breast cancer, the calcified lesion could not be identified by US alone. By fusing US with 18F-FDG PET/CT, which had been performed in advance, the location of the lesion could be estimated and marked, which benefited planning an appropriate surgery. The fusion of US and 18F-FDG PET/CT was a simple and noninvasive method for identifying the lesions detected by 18F-FDG PET/CT.

scholarly journals Diagnostic Performance of 18F-FDG PET or PET/CT for Detection of Post-Transplant Lymphoproliferative Disorder: A Systematic Review and a Bivariate Meta-Analysis

Diagnostics ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 101
Author(s):  
Veronika Ballova ◽  
Barbara Muoio ◽  
Domenico Albano ◽  
Francesco Bertagna ◽  
Luca Canziani ◽  
...  
Keyword(s):  
Systematic Review ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Lymphoproliferative Disorder ◽  
Diagnostic Performance ◽  
Meta Analysis ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg

Background: Some studies evaluated the diagnostic performance of fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography or positron emission tomography/computed tomography (PET or PET/CT) for the detection of post-transplant lymphoproliferative disorder (PTLD). As there is no clear consensus about the diagnostic accuracy of these imaging methods, we performed a meta-analysis on this topic. Methods: A comprehensive computer literature search of PubMed, Embase, and Cochrane library databases through December 2019 was performed. Pooled sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR−), and diagnostic odds ratio (DOR) of 18F-FDG PET or PET/CT for detection of PTLD were calculated. Results: Five studies reporting data on the diagnostic performance of 18F-FDG PET or PET/CT in 336 transplant recipients were included in the systematic review and bivariate meta-analysis. Pooled sensitivity and specificity for detection of PTLD were 89.7% (95% confidence interval (95%CI): 84.6–93.2%) and 90.9% (95%CI: 85.9–94.3%), respectively. Pooled LR+, LR−, and DOR were 8.9 (95%CI: 5.7–14), 0.13 (95%CI: 0.08–0.2), and 70.4 (95%CI: 35.4–140), respectively. A significant heterogeneity among studies was not detected. Conclusions: Despite limited literature data, 18F-FDG PET or PET/CT demonstrated good diagnostic performance for the detection of PTLD, but large prospective studies are needed to strengthen these findings.

scholarly journals The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor

PLoS ONE ◽  
2017 ◽  
Vol 12 (8) ◽  
pp. e0183048 ◽  
Author(s):  
Juliana Maynard ◽  
Sally-Ann Emmas ◽  
Francois-Xavier Ble ◽  
Herve Barjat ◽  
Emily Lawrie ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Non Invasive ◽  
Positron Emission ◽  
18F Fdg ◽  
Pharmacologically Active ◽  
Active Dose
Sign in / Sign up

Export Citation Format

Share Document